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Background
Vaccination against liver stage malaria antigens can induce
T cell-mediated immunity to the disease [1]. A viral vector
vaccination regime undergoing Phase 2b clinical testing
uses chimpanzee adenovirus 63 (ChAd63) and Modified
Vaccinia virus Ankara (MVA) encoding liver stage antigen
Thrombospondin-Related Adhesion Protein (TRAP) fused
to a malaria multi-epitope string (ME). This regime
induces high frequencies of antigen-specific T cells, pro-
viding 21% sterile protection and a delay to patent parasi-
taemia in a further 36% of vaccinees, following controlled
human Plasmodium falciparum malaria infection (CHMI).
Monofunctional IFNg-producing CD8+ T cells correlate
with vaccine-induced protection but the associated pro-
tective mechanisms remain unidentified [2]. Developing
standardized immunological and functional assays is a
research-specific aim of the WHO’s Malaria Vaccine
Technology Roadmap, with emphasis on novel immunoas-
says for investigation of cellular products reflecting cell-
mediated malaria immunity [3]. Development of an in
vitro parasite killing assay is underway, which quantifies
cell-mediated killing of Plasmodium-infected human hepa-
tocytes and investigates the underlying functional mechan-
isms. Additionally, the assay aims to compliment in vivo
CHMI studies.
Materials and methods
Human hepatoma cell lines were infected with transgenic
P. berghei sporozoites expressing TRAP from P. falciparum.
Freshly separated peripheral blood mononuclear cells from
partial-HLA class I matched ChAd63.MVA ME-TRAP
human vaccinees were enriched for CD8+ T cell popula-
tions. Following hepatocyte infection, enriched CD8+
T cells were added and incubated overnight. Level of infec-
tivity was measured by flow cytometry through expression
of GFP under a P. berghei promotor. TRAP-specific killing
was calculated by subtraction of non-specific killing in wild
type P. berghei-infected hepatocytes.
Results
Transgenic P. berghei sporozoites with full replacement of
wild type TRAP infect human hepatoma cells at >1% fre-
quency. Preliminary results measure a 9.5-22% TRAP-
specific reduction of infected hepatocytes after addition of
CD8+ T cells from ChAd63.MVA ME-TRAP vaccinees.
Equivalently, TRAP-specific parasite killing was not
detected following addition of CD8+ T cells from control
volunteers. Conclusions Successful use of transgenic para-
sites and the preliminary results obtained provide proof of
assay concept for this in vitro system. Further optimization
will permit the investigation of cell-mediated parasite kill-
ing of CD8+ T cells from a larger number of vaccinees and
extend to exploration of vaccine-induced mechanisms of
protection.
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